Oncology and Hematology - Prova Education

Episodes 81-94 of 94

Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
MinuteCE®
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Risk-Stratification in Newly Diagnosed CLL
Risk-Stratification in Newly Diagnosed CLL
MinuteCE®
Risk-Stratification in Newly Diagnosed CLL
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
Mutational Testing to Guide Therapy in CLL: Why and When
Mutational Testing to Guide Therapy in CLL: Why and When
MinuteCE®
Mutational Testing to Guide Therapy in CLL: Why and When
1.25 program credits
- Talha Munir, PhD
1.25 program credits
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
MinuteCE®
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
1.25 program credits
- William Wierda, MD, PhD
1.25 program credits
Combination Therapy for CLL: What Evidence Do We Have?
Combination Therapy for CLL: What Evidence Do We Have?
MinuteCE®
Combination Therapy for CLL: What Evidence Do We Have?
1.25 program credits
- William Wierda, MD, PhD
1.25 program credits
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
MinuteCE®
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
CME/CE
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
1.00 credit
- Josep Tabernero, MD, PhD
- Sara Lonardi, MD
- Zev A. Wainberg, MD
1.00 credit
Advancements in GU Cancers: Key Data from AUA 2024
Advancements in GU Cancers: Key Data from AUA 2024
CME/CE
Advancements in GU Cancers: Key Data from AUA 2024
0.50 credits
- Jason Hafron, MD
- Carissa Chu. MD
0.50 credits
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
CME/CE
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
0.50 credits
- Javier Cortes, MD, PhD
- Komal Jhaveri, MD, FACP
0.50 credits
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
CME/CE
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
0.25 credits
- Jeffrey V. Matous, MD
0.25 credits
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
CME/CE
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
0.50 credits
- Jeffrey V. Matous, MD
- Donna Catamero, NP
- Ajai Chari, MD
0.50 credits
Advances in Minimally Invasive Screening for Lung Cancer
Advances in Minimally Invasive Screening for Lung Cancer
CME/CE
Advances in Minimally Invasive Screening for Lung Cancer
0.25 credits
- Julie A. Barta, MD, ATSF
- Peter J. Mazzone, MD, MPH, FCCP
0.25 credits
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
CME/CE
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
- Thomas F. Patterson, MD, FACP, FIDSA
- George Thompson III, MD, FIDSA
Invasive Fungal Infections: More Common Than You Think
Invasive Fungal Infections: More Common Than You Think
CME/CE
Invasive Fungal Infections: More Common Than You Think
- Peter G. Pappas, MD, FACP
- Thomas F. Patterson, MD, FACP, FIDSA

Previous
1
2
…
4
5
6
Next

6/6